Literature DB >> 10884579

Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes.

R Mehvar1, R O Dann, D A Hoganson.   

Abstract

A macromolecular prodrug of methylprednisolone (MP) was synthesized by conjugating MP with dextran with a M(W) of 70000 through a succinic acid linker. It has been shown previously that the dextran-MP conjugate (DMP) releases MP directly or indirectly through formation of methylprednisolone succinate (MPS) which is further hydrolyzed to MP. To investigate the suitability of DMP conjugate as a prodrug of MP for systemic administration, the kinetics of hydrolysis of the conjugate was studied in vitro in rat blood and liver lysosomes. In blood, the hydrolysis of MPS to MP was approximately ten-fold faster than that in buffer. However, the hydrolysis rate constants of DMP conjugate to MP or MPS in blood were not different from those in buffer. Overall, the hydrolysis of DMP in the rat blood occurred with a half life of approximately 25 h. Hydrolysis of MPS to MP also occurred in the liver lysosomal fraction, but not in the control samples lacking lysosomes. However, the rate constants for the hydrolysis of DMP conjugate to MP and MPS in the lysosomal fraction were not significantly different from those in the control samples. These data suggest that the slow hydrolysis of DMP conjugate to MP or MPS in both rat blood and liver lysosomes occurs mostly, if not completely, via chemical hydrolysis. However, the conversion of MPS to MP is apparently enzymatic. The data may have significant implications for systemic administration of the prodrug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884579     DOI: 10.1016/s0168-3659(00)00234-0

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates.

Authors:  Suman Penugonda; Anil Kumar; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 2.  Development of macromolecular prodrug for rheumatoid arthritis.

Authors:  Fang Yuan; Ling-dong Quan; Liao Cui; Steven R Goldring; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

3.  Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: immunosuppressive effects after in vivo administration to rats.

Authors:  R Mehvar; D A Hoganson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

4.  Liquid chromatography-tandem mass spectrometry for the determination of methylprednisolone in rat plasma and liver after intravenous administration of its liver-targeted dextran prodrug.

Authors:  Shuang-Qing Zhang; Helen R Thorsheim; Suman Penugonda; Venkateswaran C Pillai; Quentin R Smith; Reza Mehvar
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-02-21       Impact factor: 3.205

5.  Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.

Authors:  Fang Yuan; Mengnan Sun; Zhengsheng Liu; Huiqin Liu; Weijian Kong; Rui Wang; Feng Qian
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

Review 6.  In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs.

Authors:  Hiraku Onishi; Yoshiharu Machida
Journal:  Molecules       Date:  2008-08-10       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.